To date therapeutic indications of anti-PD1/PDL1 combinations with anti-angiogenetic agents include RCC (pembrolizumab or avelumab plus axitinib), NSCLC (atezolizumab plus bevacizumab plus chemotherapy), hepatocellular carcinoma (atezolizumab plus bevacizumab). Here, PDCD1 is linked to renal cell carcinoma.